Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC decreased its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 64.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,658 shares of the company’s stock after selling 49,952 shares during the period. MetLife Investment Management LLC’s holdings in Sana Biotechnology were worth $45,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock valued at $5,206,000 after purchasing an additional 26,601 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Sana Biotechnology by 44.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock valued at $2,538,000 after buying an additional 478,596 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Sana Biotechnology by 161.7% in the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after buying an additional 730,699 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock worth $1,722,000 after acquiring an additional 8,666 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Sana Biotechnology by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company’s stock worth $549,000 after acquiring an additional 9,905 shares during the period. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $1.81 on Friday. The company has a 50-day moving average of $1.93 and a two-hundred day moving average of $2.49. The firm has a market cap of $408.11 million, a PE ratio of -1.29 and a beta of 1.75. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $9.49.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SANA shares. Citizens Jmp upgraded shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 18th. Jefferies Financial Group began coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.